Ginkgo Bioworks Holdings, Inc. current report, 10 March 2023

Full document

Ginkgo Bioworks Holdings, Inc. — Form 8-K Summary

Business context and reporting period

Ginkgo Bioworks Holdings, Inc. filed this Form 8-K on March 10, 2023, under Item 7.01, Regulation FD Disclosure. The disclosure addresses the closure of Silicon Valley Bank (SVB) and the Company’s exposure to SVB. The relevant financial reference date is December 31, 2022.

Key financial metrics and liquidity

  • Approximately $74 million of cash held by the Company’s wholly owned subsidiary, Zymergen Inc., was deposited at SVB.
  • The SVB balance represented approximately 6% of the Company’s cash and cash equivalents as of December 31, 2022.
  • The Company stated that it did not maintain any other material accounts or lines of credit with SVB.
  • This filing does not provide revenue, profit, cash-flow, margin, debt, or updated liquidity figures beyond the disclosed cash concentration.

Material changes versus the prior comparable period

The filing does not present comparative operating or financial results. It discloses a banking-counterparty exposure following SVB’s closure but does not quantify any realized loss, impairment, or other financial impact.

Guidance, outlook, risks, contingencies, and unusual items

  • The principal risk disclosed is temporary or permanent loss of access to the approximately $74 million SVB deposit balance.
  • The filing does not provide management guidance or an updated outlook.
  • The disclosure does not state whether the SVB funds were recovered, insured, or otherwise available to the Company as of the filing date.
  • The information was furnished under Regulation FD and was not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings except where expressly stated.

Facts investors should verify

  1. Whether the approximately $74 million SVB deposit was fully accessible or ultimately recovered.
  2. Any subsequent accounting recognition of a loss, impairment, or restricted cash balance related to the SVB exposure.
  3. The Company’s updated cash and cash-equivalent balance and liquidity position after March 10, 2023.
  4. Whether the SVB closure affected Zymergen’s operations, payments, payroll, or access to banking services.